Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Early Efficacy Response Rate of Leflunomide According to the Initial Dosing Regimen in the Treatment of Naive-DMARD (Disease Modifying Anti-Rheumatic Drug) Early RA (Rheumatoid Arthritis)-Patients

NCT00596206 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00596206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00596206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Early Efficacy Response Rate of Leflunomide According to the Initial Dosing Regimen in the Treatment of Naive-DMARD (Disease Modifying Anti-Rheumatic Drug) Early RA (Rheumatoid Arthritis)-Patients
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2007
Completion date
October 31, 2009
Enrollment
124 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid